Strong deliveries in Q4, sales +32% vs cons, EBIT +70% Guides for strong sales and order intake in 2...
Healthcare services in Central and Eastern Europe and India 19% sales CAGR and 21% adj.
AVTECH published preliminary figures for Q4 2024, which showed net sales increased 22% y/y, with EBI...
Q4e sales -4% y-o-y (-11% org.), adj. EBITA margin 4.
Q4e sales SEK 50m, flat y-o-y, EBIT SEK -0.6m (-2.1m) Somewhat more cautious on Perf.
Q4e: orders flat, sales -2%, EBITA margin -2.9pp y-o-y EU PMI remains below 50, push forward recover...
This afternoon, Føroya Banki raised its 2024 net profit guidance to DKK 302-312m (previously DKK 275...
Redeye gives an initial take on the first clinical results from the CARMA study with ELC-301.
EE headwinds from programme end-of-life and automotive market Mix effects and major FX revaluations ...
Crypto prices are on a strong run We raise our '25e-'26e AUM and adj.
Redeye provides its thoughts on the rights issue.
Redeye comments on the preliminary Q4 figures from Formpipe.
Redeye expects Smart Eye’s Q4 report, due 18 February, to show a 4% y/y sales growth and an EBITDA i...
Redeye comments on Freemelt ahead of its Q4 results.
Strong Q4 with a beat on all headline items... ...adds more fuel to '25e growth: guidance remains to...
Redeye provides a short comment on what is to be interpreted as a reverse profit warning from Cheffe...
Duell delivered slightly better figures than we had expected for the seasonally quiet Q1 of its fisc...
Analyst Group har med Nosa Plugs ingått avtal om kontinuerlig analysbevakning, innefattande bl.
Redeye briefly comments on MedCap releasing preliminary Q4 2024 figures, significantly undershooting...
Ahead of Fiskars' Q4 report, we nudge up our Q4 estimates slightly and expect the company to reach t...
